The Sickle Cell Disease Association of America, Inc., (SCDAA) is aware of the recent Pfizer announcement regarding the withdrawal of OXBRYTA ® (voxelotor) for the treatment of sickle cell in all markets. We await further information, and an SCDAA Medical and Research Advisory Committee (MARAC) statement will be forthcoming. We are working diligently through MARAC and with our partners to gather credible information to share with the SCD community. Safety is our utmost concern. Because there are currently so many unknowns, we urge you to discuss any concerns you may have with your health care provider. Read the Pfizer statement.
